Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | TTK | P33981 | 1/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 7/20 | 0.44 |
| ▸ | WNT1 | P04628 | 5/20 | 0.44 |
| ▸ | AXL | P30530 | 1/20 | 0.43 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.42 |
| ▸ | PIM1 | P11309 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4220579 | 0.88 | MAPK1 (0.42) | DYRK1AMAP2K4MAPK1ABL1 | |
| SCHEMBL4230063 | 0.87 | ABL1 (0.48) | GSK3BMAP2K4MAPK1ABL1 | |
| SCHEMBL4225132 | 0.85 | MAP2K4 (0.47) | MAP2K4MAPK1ABL1 | |
| SCHEMBL4222889 | 0.85 | LRRK2 (0.40) | MAP2K4PIM1MAPK1ABL1LRRK2 | |
| SCHEMBL4219380 | 0.85 | MAPK1 (0.52) | MAPK1 | |
| SCHEMBL4229006 | 0.84 | MAP2K4 (0.43) | MAP2K4MAPK1LRRK2 | |
| SCHEMBL4219329 | 0.84 | CYP2C9 (0.42) | GSK3BDYRK1AMAP2K4MAPK1 | |
| SCHEMBL4219255 | 0.84 | MAP2K4 (0.49) | GSK3BMAP2K4MAPK1 | |
| SCHEMBL14098861 | 0.83 | MAPK14 (0.44) | GSK3BCYP1A2MAPK1ABL1 | |
| SCHEMBL4228198 | 0.83 | MAP2K4 (0.45) | GSK3BMAP2K4MAPK1ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090023725-A1 | Fused Heteroaryl Derivatives for Use as P38 Kinase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2009-01-22 | — | — | US | disclosed |
| US-20090023725-A1 | Fused Heteroaryl Derivatives for Use as P38 Kinase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2009-01-22 | — | — | US | disclosed |
| EP-1708996-B1 | FUSED HETEROYRAL DERIVATIVES FOR USE AS P38 KINASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2008-08-27 | — | — | EP | disclosed |
| EP-1708996-B1 | FUSED HETEROYRAL DERIVATIVES FOR USE AS P38 KINASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2008-08-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023725-A1 | Fused Heteroaryl Derivatives for Use as P38 Kinase Inhibitors | MAPK1, MAPKAPK2, MAPK7 | GSK3B 881/4885CYP1A2 1956/4885TTK 241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.